Immutep is listed on the Australian Stock Exchange (ASX:IMM) and on the NASDAQ Global Market (NASDAQ:IMMP) in the U.S. (ADR's).
We are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S.
We are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel.
Our objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. We have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Our lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for breast cancer and melanoma.
Latest Media Releases
22/07/2024 08:12:00
-- Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA® (pembrolizumab), MSD…
12/07/2024 08:48:00
Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatmen…
Latest News
Market Reports /
by Peter Milios -
A year ago
24 May 2023 - At the closing bell, the S&P/ASX 200 was 0.63 per cent lower at 7,213.80. This drop was primarily influenced by the materials and healthcare sectors.
Market Reports /
by Peter Milios -
A year ago
24 May 2023 - Swiss banks UBS and Credit Suisse are nearing the completion of their merger, with regulatory approval expected by 31 May.
Interviews /
by Paul Sanger -
A year ago
19 May 2023 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses the significance of recent announcements on the back of a surge in trading volume.
Market Reports /
by Peter Milios -
A year ago
18 May 2023 - At the closing bell, the S&P/ASX 200 was 0.52 per cent higher at 7,236.80. Nufarm's (ASX:NUF) shares rallied 14.2 per cent to $6.05 after announcing a 7 per cent incr…
Market Reports /
by Peter Milios -
A year ago
18 May 2023 - According to the Australian Bureau of Statistics, the economy experienced a loss of 4,300 jobs in the previous month, which was contrary to economists' predictions of…
Market Reports /
by Peter Milios -
A year ago
16 May 2023 - On Tuesday, at the closing bell, the S&P/ASX 200 was 0.45 per cent lower at 7,234.70, as the healthcare, tech, and consumer staples sectors witnessed drops, which cou…
Market Reports /
by Peter Milios -
A year ago
16 May 2023 - The Reserve Bank's minutes for May indicate that the central bank is committed to reducing inflation. The Board expressed its determination to take the necessary acti…
Market Reports /
by Peter Milios -
A year ago
17 Apr 2023 - At the closing bell, the S&P/ASX 200 was 0.27 per cent higher at 7,381.50, led by gains in the financials and real estate sectors.
Market Reports /
by Peter Milios -
A year ago
17 Apr 2023 - Nine out of the eleven sectors are trading higher today. Information technology is surging on the back of gains from WiseTech Global (ASX:WTC), Xero (ASX:XRO), and Al…
Market Reports /
by Peter Milios -
A year ago
31 Mar 2023 - At the closing bell, the S&P/ASX 200 was 0.78 per cent higher at 7,177.80, led by the materials sector, which saw BHP Group's (ASX:BHP) shares rise by 2.5 per cent.
Market Reports /
by Peter Milios -
A year ago
31 Mar 2023 - At noon, the S&P/ASX 200 is 0.71% higher at 7,173, with materials and healthcare sectors leading the gains. Syrah Resources (ASX:SYR), Block (ASX:SQ2), and De Grey Mi…
Market Reports /
by Peter Milios -
A year ago
14 Mar 2023 - At the closing bell, the S&P/ASX 200 was 1.4 per cent lower at 7,008.9, a three-month low. The fall was mainly due to concerns about a financial crisis after the coll…
Market Reports /
by Peter Milios -
A year ago
14 Mar 2023 - Earlier today, the S&P/ASX 200 stock index of Australia experienced a decline of 2.1 per cent and hit a new low of 6956.7, which is close to its lowest point of the y…
Interviews /
by Tim McGowen -
A year ago
01 Mar 2023 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses data from SITC, the strategy to take Efti to market and milestones for 2023.
Market Reports /
by Peter Milios -
A year ago
06 Feb 2023 - All sectors besides Energy and Materials are trading lower today, after the US sectors fell on Friday due to a strong jobs report, which caused some investors to worr…
Market Reports /
by Peter Milios -
A year ago
30 Jan 2023 - The global race for lithium, a commodity crucial for the electric vehicle (EV) industry, has intensified as German Chancellor Olaf Scholz signed an agreement with Arg…
Market Reports /
by Peter Milios -
A year ago
08 Dec 2022 - Goldman Sachs have extended their bearish views on lithium, believing that the prices are expected to decline from the second half of 2023.